University of Chicago
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, University of Chicago sits in the top decile of US sponsors by registered trial count (#41 of 15,742 sponsors by registered trial count).
University of Chicago: 796 sponsored US clinical trials, 158 recruiting.
University of Chicago sponsors 796 registered US clinical trials on ClinicalTrials.gov, 158 of them currently recruiting, and 451 completed. 67 of these trials are in Phase 3-4 (later-stage) and 293 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Prostate Cancer, with 11 trials.
Top-decile sponsor footprint
University of Chicago ranks in the top decile of sponsors by registered trial count (#41 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
451 of 562 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (80.2%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
796 total, page 16 of 16
Improving Diabetes Care Collaboratively in the Community
NCT00359996
Gemcitabine, Cisplatin, and Amifostine Following Surgery in Treating Patients With Locally Advanced Bladder Cancer
NCT00006105
SU5416 Compared to Dexamethasone in Treating Patients With Progressive Prostate Cancer That Has Not Responded to Hormone Therapy
NCT00006002
Bryostatin 1 Plus Paclitaxel in Treating Patients With Stage IIIB, Stage IV, or Recurrent Non-small Cell Lung Cancer
NCT00005849
Bcl-2 Antisense Oligodeoxynucleotide G3139 and Paclitaxel in Treating Patients With Recurrent Small Cell Lung Cancer
NCT00005032
Orthotopic Liver Transplantation Using a Living Donor
NCT00152607
Oxaliplatin Combined With Fluorouracil and Leucovorin in Treating Patients With Recurrent or Metastatic Cancer of the Esophagus or Stomach
NCT00004127
Oxaliplatin in Treating Patients With Metastatic Bladder Cancer
NCT00004203
Irinotecan and Cyclosporine in Treating Patients With Metastatic, Advanced or Locally Recurrent Colorectal Cancer
NCT00003950
Intravenous Immunoglobulin (IVIG) for Treatment of Unexplained Secondary Recurrent Miscarriage
NCT00606905
Paclitaxel and Oxaliplatin in Treating Patients With Recurrent or Advanced Non-small Cell Lung Cancer
NCT00004126
O6-benzylguanine Followed by Surgery in Treating Patients With Solid Tumors That Can Be Removed During Surgery
NCT00003766
Combination Chemotherapy in Treating Patients With Stage IV Locally Advanced or Metastatic Bladder Cancer
NCT00005086
Concomitant Chemoradiotherapy With Weekly Paclitaxel and Vinorelbine and Granulocyte Colony Stimulating Factor (GCSF) Support in Patients With Advanced Breast Cancer
NCT00724386
Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Melanoma or Metastatic Kidney Cancer
NCT00004135
Dolastatin 10 in Treating Patients With Metastatic Or Recurrent Liver, Bile Duct, or Gallbladder Cancer
NCT00003557
Chemotherapy Plus Biological Therapy Followed By Peripheral Stem Cell Transplantation in Treating Patients With Hematologic Cancer
NCT00004145
Developing Criteria for Cortical Resections
NCT00152659
Combination Chemotherapy Plus Biological Therapy in Treating Patients With Metastatic Melanoma
NCT00004141
Detection of Melanoma Markers in Lymph Nodes or Peripheral Blood of Patients With Melanoma
NCT00004153
Aminocamptothecin in Treating Patients With Stomach Cancer or Cancer of the Esophagus
NCT00003192
Effects of Alcohol History on Effects of Sevoflurane and Nitrous Oxide - 13
NCT00000261
Subjective/Psychomotor/ Effects of Combined Alcohol & Nitrous Oxide - 16
NCT00000264
Leuprolide in Treating Adults With Hypogonadotropism
NCT00004438
Subjective Effects of Nitrous Oxide in Dental Patients - 17
NCT00000265
Effects of Behavioral Contingencies on Effects of Nitrous Oxide - 12
NCT00000260
Vaccine Therapy and Interleukin-12 in Treating Patients With Metastatic Melanoma
NCT00002952
Effects of Combined Alcohol and Nitrous Oxide Intake - 15
NCT00000263
Combination Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Epithelial Ovarian Cancer or Primary Peritoneal Cancer
NCT00003136
Irinotecan and Paclitaxel in Treating Patients With Metastatic or Recurrent Cancer
NCT00002939
Effects of Combined Sevoflurane and Nitrous Oxide Inhalation - 14
NCT00000262
Sevoflurane vs Nitrous Oxide Inhalation at Subanesthetic Concentrations - 11
NCT00000259
Vinorelbine and Paclitaxel Plus Radiation Therapy in Treating Patients With Advanced Cancer Arising in the Pelvis
NCT00002949
Chemotherapy Plus Radiation Therapy in Treating Patients With Head and Neck Cancer
NCT00002951
Role of Instructions in Nitrous Oxide Effects and Choice - 10
NCT00000258
Effects of Alcohol History on Effects of Nitrous Oxide - 9
NCT00000257
Reinforcing Effects of Brief Exposures to Nitrous Oxide - 8
NCT00000256
Differential Acute Tolerance Development to Effects of Nitrous Oxide - 7
NCT00000255
Isoflurane at Subanesthetic Concentrations - 6
NCT00000254
Effects of Nitrous Oxide: A Dose-Response Analysis - 5
NCT00000253
Leuprolide in Determining the Cause of Gonadotropin Deficiency
NCT00004426
Lack of Acute Tolerance Development to Effects of Nitrous Oxide - 4
NCT00000252
Effects of Subanesthetic Concentrations of Isoflurane/Nitrous Oxide - 3
NCT00000251
Cold Water Immersion Modulates Reinforcing Effects of Nitrous Oxide - 2
NCT00000250
Effects of Subanesthetic Concentrations of Nitrous Oxide - 1
NCT00000249
Chicago Childhood Diabetes Registry
NCT00204009
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 137 |
| Phase 2 | 156 |
| Phase 3 | 14 |
| Phase 4 | 53 |
Therapeutic Areas
What is open in the University of Chicago pipeline
158 recruiting of 796 indexed (20% open); 451 completed (57%).
Phase mix: 67 late (III/IV) vs 293 early (I/II) (early-phase heavy).
Top condition: Prostate Cancer (11 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
University of Chicago: open-pipeline peers nationwide
Peers matched on 796 registered trials and 20% open enrollment, not the therapeutic-area sidebar.
University of Chicago sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 796 trials (± recruiting share)
- Dana-Farber Cancer Institute · 781 trials · 14% recruiting
- University of California, San Diego · 775 trials · 18% recruiting
- University of Utah · 818 trials · 17% recruiting
- University of Texas Southwestern Medical Center · 837 trials · 19% recruiting
Sponsors near 20% open enrollment (± trial volume)
- Acera Surgical · 20% recruiting · 5 trials
- Align Technology · 20% recruiting · 5 trials
- AltruBio · 20% recruiting · 5 trials
- Alvernia University · 20% recruiting · 5 trials
Related
What to do with this University of Chicago page
796 registered trials is a research-attention snapshot, not an endorsement of University of Chicago or any single study.
- 158 of University of Chicago's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Prostate Cancer is the condition University of Chicago studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Prostate Cancer trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. University of Chicago pipeline card: 796 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.